|
|
Article: 3M Announces Positive Results from Phase III Trials On Aldara for AK and sBCC Skin Conditions.
- Article from:
- Business Wire
- Article date:
- March 3, 2003
CopyrightCOPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
ST. PAUL, Minn.--(BUSINESS WIRE)--March 3, 2003
- Company on Track for Mid-Year FDA Submission -
3M today announced positive clinical results in pivotal Phase III studies of Aldara (imiquimod) Cream, 5%, an immune response modifier (IRM), for multiple actinic keratoses (AK) and superficial basal cell carcinoma (sBCC). These potentially serious skin conditions are a direct result of cumulative sun exposure.
In the AK trials, the median percent reduction in the number of AK lesions counted at baseline was 83 percent in the Aldara treatment group versus 0 percent in the placebo group. The complete ...